Robert Duggan

About Robert Duggan

Robert Duggan is a serial entrepreneur; he led the 2015 sale of biotech firm Pharmacyclics to AbbVie for $21 billion in cash and stock.

The success of Pharmacyclics' cancer drug Imbruvica made him a billionaire in 2013.

Duggan, whose son died from brain cancer, became passionate about Pharmacyclic's cancer fighting drugs and first invested in 2004.

His enthusiasm for investing began four decades earlier in a corporate finance class he took at the University of California at Santa Barbara.

In 2020, Duggan bought $63 million of shares in Nasdaq-listed Summit Therapeutics, a small biotech company, and became its CEO.

Duggan also sits on the board of Pulse Biosciences, of which he is the largest individual shareholder.